Mirum Pharmaceuticals (MIRM.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec1

Mirum Pharmaceuticals Launches Phase 2 BLOOM Clinical Trial for Fragile X Syndrome Treatment MRM-3379

13:10

Nov7

Mirum to Present LIVMARLI and Volixibat Clinical Programs at AASLD

13:10

Nov5

Condulis recommends stocks including Soleno Therapeutics, Cytokinetics and Mirum Pharmaceuticals

15:23

Joseph Thome Rates Mirum Pharmaceuticals as Buy

02:36

Mirum Pharmaceuticals released FY2025 Q3 earnings on November 4 After-Market (EST), actual revenue USD 133.01 M (forecast USD 130.5 M), actual EPS USD 0.0499 (forecast USD -0.14)

00:00

Mirum Pharmaceuticals released FY2025 9 Months Earnings on November 4 After-Market EST, with actual revenue of USD 372.38 M and EPS of USD -0.368

00:00

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 133.01 M, Net Income 2.905 M, EPS 0.0499

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 127.79 M, Net Income -5.861 M, EPS -0.1178

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 111.59 M, Net Income -14.68 M, EPS -0.3002

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More